Meningococcal Disease: Recognition, Treatment, Prevention

Invasive meningococcal disease is a rare but life-threatening infection that is largely preventable through vaccination against serogroups A, B, C, W, and Y. Long-term sequelae — including physical, neurologic, psychological, and functional complications — may occur among survivors. Despite antimicrobial treatment, case-fatality rates remain approximately 10%-15%, and up to 20% of survivors experience severe, long-term sequelae.Tina Q. Tan, MDMedscape spoke with Tina Q. Tan, MD, attending physician in the Division of Infectious Diseases and medical director of the International Adoptee Clinic at Ann & Robert H. Lurie Children's Hospital of Chicago; professor of pediatrics at Northwestern University Feinberg School of Medicine; and immediate past president of the Infectious Diseases Society of America, about changing US epidemiology of invasive meningococcal disease and practical considerations for recognition, empiric treatment, postexposure prophylaxis, vaccination, and follow-up.Over the past few years, how has the epidemiology of invasive meningococcal disease in the US changed in terms of age distribution, risk groups, and serogroups, and what should frontline clinicians watch for in 2026 and beyond?Meningococcal disease incidence in the United States increased from 0.06 cases per 100,000 population in 2021 to 0.13 cases per 100,000 in 2023. Although infants younger than 1 year had the highest meningococcal disease incidence in every year from 2020 through 2023, the largest increase in incidence during that period occurred among people aged 45-64 years. The recent increase in disease disproportionately affected Black individuals and those with HIV.The recent Neisseria meningitidis serogroup Y increase has contributed substantially to the changing epidemiology of invasive meningococcal disease in the United States. The expanding ST-1466 N meningitidis strain has particularly affected adults aged 30-60 years and has often presented with bacteremia, septic arthritis, pneumonia, or septic shock rather than meningitis. Frontline clinicians should remain alert to clinical presentations of invasive disease outside the traditionally expected adolescent age group.Many patients initially present with nonspecific symptoms. What practical red flags or decision points do you use in triage or primary care to distinguish early meningococcal disease from viral illness and decide when to escalate to urgent evaluation, imaging, and lumbar puncture?Symptoms of meningococcal disease may include fever, headache, stiff neck, altered mental status, sepsis, and rash. The disease can progress rapidly, and suspected meningococcal disease requires prompt empiric treatment. One issue is that patients may wait a long time before seeking medical attention, and with this disease, this delay places them at very high risk for severe complications and death. Some red flags include severe headache with altered mental status or other neurologic abnormalities and rapidly developing petechial or purpuric rash. These findings should prompt urgent evaluation.Current guidance recommends rapid empiric treatment with extended spectrum cephalosporins, often in combination with other agents. Where do you see the gray areas in antibiotic selection, duration, and the role of corticosteroids, particularly in mixed or uncertain bacterial meningitis presentations?Most patients are treated for possible meningitis and sepsis and are placed on a combination of broad- and extended-spectrum antibiotics. Treatment can be tailored once culture and polymerase chain reaction testing results are available. For confirmed meningococcal meningitis, the antibiotic course is generally 5-7 days. Patients with complicated infection or another focal invasive manifestation may require an individualized treatment plan that may require a longer course of antibiotic therapy.For confirmed meningococcal meningitis, adjunctive corticosteroid therapy is not routinely continued; however, corticosteroid therapy may be initiated empirically when acute bacterial meningitis is suspected, and the causative pathogen has not yet been identified. If corticosteroids are used during empiric management of suspected bacterial meningitis, they should be administered before or concurrently with the first antimicrobial dose and should not delay antibiotics.Postexposure prophylaxis recommendations can be complex, especially for healthcare workers and congregate settings. What are the most common misunderstandings you encounter around who needs chemoprophylaxis, which agents to choose, and how you handle equivocal exposures or delayed presentations?One common misunderstanding is that close contacts need postexposure prophylaxis regardless of immunization status. Eligible contacts include household members, childcare or preschool contacts, and people with direct exposure to the patient's oral or respiratory secretions, such as kissing or sharing eating utensils, during the 7 days before illness onset.Healthcare personnel should receive chemoprophylaxis after unprotected mucous-membrane exposure to respiratory secretions during mouth-to-mouth resuscitation, endotracheal intubation or airway management, or open airway suctioning. The patient is considered noninfectious 24 hours after starting effective antimicrobial therapy.For airline exposures, chemoprophylaxis should be considered for passengers seated directly next to the index patient on a flight lasting more than 8 hours. On flights of any duration, prophylaxis should be considered for passengers seated within one seat of a patient who was coughing or vomiting during the flight. If there is concern about an equivocal exposure or delayed presentation, I tend to give chemoprophylaxis because of the risk for severe disease.Chemoprophylaxis should be started as soon as possible, ideally within 24 hours after the index patient is identified. Prophylaxis administered more than 14 days after illness onset in the index patient is likely to provide limited or no benefit. Standard chemoprophylaxis options include rifampin, ceftriaxone, azithromycin, and ciprofloxacin. In areas that meet US CDC thresholds for ciprofloxacin resistance, public-health authorities should preferentially consider rifampin, ceftriaxone, or azithromycin instead of ciprofloxacin.With newer vaccine options, including MenABCWY, and updated immunization guidance, how are you personally approaching vaccination in adolescents, high-risk adults, and travelers, and where do you think the evidence still leaves room for interpretation or individualized decision-making?I recommend meningococcal vaccination for adolescents, adults at increased risk, and travelers going to areas where meningococcal disease is highly prevalent, including people traveling to Mecca, Saudi Arabia, for Hajj or to areas of sub-Saharan Africa. Individualized decision-making remains appropriate for travelers based on destination, itinerary, duration of travel, activities, and risk for exposure.For survivors of invasive meningococcal disease, what does your longitudinal follow-up look like in terms of monitoring for hearing loss, neurocognitive issues, mental health, and functional outcomes, and how well do current guidelines support this aspect of care?Survivors of invasive meningococcal disease are followed for months to years, depending on the severity of illness and the complications they have experienced. Long-term sequelae, including hearing loss, neurologic complications, cognitive effects, mental-health consequences, and functional impairment, can occur after invasive meningococcal disease. In my experience, current follow-up guidance supports monitoring for complications and referral for relevant services reasonably well.What systems-level changes, such as emergency department pathways, vaccination prompts in electronic health records, and community outreach, and what communication strategies have you found most effective for improving timely recognition, vaccination uptake, and adherence to follow-up after meningococcal disease?I have found that system-level approaches that may support timely recognition, vaccination uptake, and follow-up after meningococcal disease include establishing emergency department treatment pathways and clinical guidance; incorporating vaccination prompts into the electronic health record; engaging local and state health departments; and seeking input from infectious diseases specialists. I also use guidance from the American Academy of Pediatrics' Red Book, along with clear communication with patients, families, and other clinicians, to support consistent care.